Vaccines and Global Health: The Week in Review :: 16 October 2021

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version A pdf of the current issue is available here:

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

SAGE October 2021 meeting highlights

Milestones :: Perspectives :: Research

 

SAGE October 2021 meeting highlights
10 October 2021
Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
4-7 October 2021
(Full report will be published in the Weekly Epidemiological Record on 17.12.2021, and only
the wording of the full report should be considered as final)

 

Report from the WHO department of Immunization, Vaccines and Biologicals
:: The Director’s report focused on equity in vaccination especially in the COVID-19 pandemic context which has exposed and exacerbated inequities in access to immunization.
:: Access to COVID-19 vaccines has been extreme in its inequity with high-income countries having
administered 35 times more vaccine doses than the low-income countries and the WHO Africa Region countries having only 3% of the population fully vaccinated.
:: While the pandemic has affected childhood immunization programmes across the world, the poorest countries have been affected the most and have been the slowest to recover.
:: Country experiences show that solutions are available and the Immunization Agenda 2030 (IA2030) well lays out the path to recovery and to building resilient immunization programmes.

 

WHO Regional updates
:: COVID-19 vaccine rollout has started in all WHO regions though the pace of vaccination varies
considerably between and within regions, driven largely by the unequal access to vaccine supply.
Fifty-six countries found predominantly in the Africa and Eastern Mediterranean regions were unable to achieve the target of fully vaccinating 10% of their populations by September 2021, largely because of lack of vaccine doses.
:: As vaccine supplies improve, the WHO regional offices and partner agencies are supporting country preparedness to overcome existing operational challenges and scale up vaccination to reach the goal of 70% coverage by June 2022.
:: Countries in all regions experienced a decline in coverage with routine childhood vaccination, though the magnitude of the decline and the speed of recovery varied.
:: All the regions have developed or are in the process of developing action plans to operationalize IA2030 in their respective regions. This will provide an opportunity to accelerate recovery and to strengthen the resilience of immunization programmes.

 

IA2030 update
:: SAGE was presented with the first progress report on the Immunization Agenda 2030, featuring
baseline data from 2019-2020, as part of an update on the operationalization of IA2030, including the framework and process for monitoring, evaluation, and accountability.
:: The WHO regional offices have developed regional strategies or frameworks aligned to IA2030, in collaboration with their Member States and regional stakeholders; most have been approved by the respective Regional Committees.
:: Progress was made with the development of the IA2030 governance and coordination process and structures, including the partnership council, the coordination group, and working groups.
:: SAGE will conduct independent annual assessments of progress and provide recommendations
for corrective actions to Member States and the relevant Working Groups.
:: SAGE recommended that relevant stakeholders conduct country-by-country analysis of programmatic bottlenecks and challenges to inform corrective actions to be taken at global, regional and national levels.
:: SAGE recommended that countries develop National Immunization Strategies aligned to the IA2030 and Regional Frameworks and establish national monitoring, evaluation, and accountability processes.

 

Poliomyelitis
:: There has been a substantial drop in wild poliovirus detections in the endemic areas in 2021 and there have been no reported cases since February 2021. SAGE emphasized the need to fully engage program resources to achieve eradication while maintaining or strengthening poliovirus surveillance.
:: SAGE expressed concern regarding ongoing transmission of circulating Vaccine Derived Poliovirus type 2 (cVDPV2), particularly in the African region, the recurrent cVDPV2 outbreaks in Nigeria, and highlighted the need for timely responses.
:: SAGE recommended a cautious approach to withdrawing oral poliovirus vaccine (OPV) from national routine immunization schedules in the pre-eradication period but acknowledged that countries in polio-free regions with high vaccination coverage may consider switching to Inactivated Poliovirus Vaccine (IPV) only schedules, including a 2-dose IPV schedule. Once adequate supply is available, the use of whole-cell pertussis hexavalent vaccines containing IPV will facilitate the use of IPV-only schedules.
:: SAGE endorsed the transition of the novel OPV type 2 vaccine (nOPV2) from initial to wider use under WHO Emergency Use Listing (EUL), based on the findings of the independent safety and genetic stability assessment.

 

COVID-19
:: Bharat Biotech’s COVID-19 Vaccine (COVAXIN) was reviewed by SAGE; a policy recommendation will be issued when the vaccine is Emergency Use listed by WHO.
:: SAGE recommended that moderately and severely immunocompromised persons should be offered an additional dose of all WHO EUL COVID-19 vaccines as part of an extended primary series since these individuals are less likely to respond adequately to vaccination following a standard primary vaccine series and are at high risk of severe COVID-19 disease.
:: For the Sinovac and Sinopharm inactivated vaccines, an additional (third) dose of the homologous vaccine should be offered to persons aged 60 and above as part of an extended primary series. The use of a heterologous platforms vaccine for the additional dose may also be considered based on vaccine supply and access considerations. When implementing this recommendation, countries should initially aim at maximizing 2-dose coverage in that population, and thereafter administer the third dose, starting in the oldest age groups.

 

The global COVID-19 vaccination strategy
:: The global COVID-19 vaccination strategy, previously reviewed by SAGE, provides the goals, the resource requirements, and describes the expected outcomes underlying the vaccination targets set for the end of 2021 and mid-2022.
:: Drawing on SAGE’s June 2021 recommendation and advancing it, given the progression of the
pandemic, the strategy prioritizes vaccination of high-risk populations and all adults and fully commits to the risk mitigation approach by calling for 70% of the world’s population fully vaccinated by mid-2022.
:: The strategy acknowledges the scientific uncertainties and the need for updates as new evidence becomes available.
:: SAGE noted that success in achieving the goals and interim targets of the strategy will require the collective and cohesive actions of all relevant stakeholders.

 

The RTS,S/AS01 malaria vaccine
:: In a joint session, SAGE and the Malaria Policy Advisory Group (MPAG) reviewed the evidence on the RTS,S/AS01 malaria vaccine and recommended that the vaccine be used for the prevention of P. falciparum malaria in children living in regions with moderate to high transmission as defined by WHO.
:: The vaccine should be provided in a schedule of 4 doses in children from the age of 5 months to reduce the burden of malaria.
:: Drawing from a growing body of evidence, countries may consider providing the RTS,S/AS01 vaccine seasonally, with a 5-dose strategy in areas with highly seasonal malaria or areas with perennial malaria transmission with seasonal peaks. When countries choose the seasonal deployment of the RTS,S/AS01 vaccine, they are strongly encouraged to document their experience, including the vaccine effectiveness, feasibility, and occurrence of any adverse
events, to feed into future guidance updates.
:: RTS,S/AS01 introduction should be considered in the context of comprehensive national malaria control plans.
:: The recommendation is based on results from an ongoing pilot programme in Ghana, Kenya and Malawi that has vaccinated more than 800 000 children since 2019. The evaluation results show that the vaccine has a favourable safety profile, is effective, and led to a substantial reduction in life-threatening severe malaria, even in settings with good coverage with insecticide treated nets, and access to treatment.
:: The pilot programme also showed that there is high demand for the vaccine, and that it can be delivered effectively through the routine child immunization programmes without affecting the uptake of other vaccines or malaria interventions. Because of its high uptake and coverage, the vaccine has been able to reach vulnerable children who are currently not protected by other
malaria control interventions.

 

Influenza vaccines
:: Influenza causes an estimated > 1 bn cases of infection, including 3-5 million episodes of severe disease and 290,000 – 650,000 deaths annually.
:: SAGE recommends that all countries consider implementing seasonal influenza vaccination based on the burden and epidemiology of disease, the cost-effectiveness of vaccination, competing public health priorities, and programmatic feasibility.
:: For countries considering the initiation or expansion of programmes for seasonal influenza vaccination, SAGE recommended that the following target groups should be considered for vaccination in no particular order of priority: health workers, individuals with specific chronic medical conditions, older adults and pregnant women.
:: Countries may consider additional (sub)populations for vaccination such as children and individuals at high risk of severe influenza living in congregate-living setting such as prisons, long-term care facilities, refugee camps, asylum seekers and group homes.
:: Vaccination in the current and prior season afforded better protection than not being vaccinated or being vaccinated in the prior season only, although protection from vaccination in the current and prior season was attenuated, particularly for the H3N2 sub-type, when compared with vaccination in the current season alone. SAGE continues to recommend annual seasonal influenza vaccination for the priority target groups.
:: Limited evidence on co-administration of inactivated seasonal influenza vaccines with COVID-19 vaccines showed no increased adverse events. Since the adult age groups targeted for seasonal influenza vaccination are also at risk for developing severe COVID-19, co-administration of an inactivated seasonal influenza vaccine and any WHO emergency use listed COVID-19 vaccine is acceptable and will maximize the uptake of both vaccines.
:: In the context of the COVID-19 pandemic, SAGE continues to recommend the prioritization of health workers and older adults as target groups for seasonal influenza vaccination during the COVID-19 pandemic, and countries should also consider prioritization of pregnant women

 

Behavioural and social drivers of vaccine uptake
:: New evidence, tools, and guidance on ‘Behavioural and social drivers (BeSD) of vaccine uptake’ to support programmes to assess and address reasons for under-vaccination were presented to SAGE.
:: SAGE recognized the importance for measuring factors contribute to low uptake and took note of the evidence-informed framework for measuring behavioural and social drivers.
:: SAGE recommended the systematic gathering and use of data on BeSD to assess the reasons for low uptake, periodic monitoring of trends.

 

Hepatitis E vaccine
:: SAGE highlighted the importance of the hepatitis E vaccination to mitigate the impact of outbreaks with the principal aim of protecting pregnant women and noted that those most affected by hepatitis E are underprivileged populations in low-resource settings.
:: SAGE encouraged manufacturers to proceed as quickly as possible with seeking WHO prequalification, this should not preclude the use of the vaccine prior to pre-qualification.
:: SAGE encouraged the continued coordination between key stakeholders and recommended that WHO work with Gavi for inclusion of hepatitis E vaccination for outbreak response and hepatitis E surveillance and diagnostics within its portfolio of support to eligible countries.

Global tuberculosis report 2021

Milestones :: Perspectives :: Research

 

TB

Global tuberculosis report 2021
14 October 2021  |
WHO Report :: 57 pages
PDF: https://apps.who.int/iris/rest/bitstreams/1379788/retrieve
Overview
Each year, the WHO Global TB Report provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.
The 2021 edition of the report has been produced in a new and more web-centric format. This is designed to make the content available in smaller (more “bite-sized”) chunks that are easier to read, digest, navigate and use. There is a short and slim report PDF with 30 pages of main content plus six short annexes. This is accompanied by expanded and more detailed digital content on web pages. The total amount of content remains similar to that of previous years.
Please note that direct comparisons between estimates of TB disease burden in the latest report and previous reports are not appropriate. The most recent time-series of estimates are published in this global TB report.
Global TB reports from previous years can be found here.

 

Top findings and messages in the 2021 report
The COVID-19 pandemic has reversed years of progress in providing essential TB services and reducing TB disease burden. Global TB targets are mostly off-track, although there are some country and regional success stories.

The most obvious impact is a large global drop in the number of people newly diagnosed with TB and reported. This fell from 7.1 million in 2019 to 5.8 million in 2020, an 18% decline back to the level of 2012 and far short of the approximately 10 million people who developed TB in 2020. 16 countries accounted for 93% of this reduction, with India, Indonesia and the Philippines the worst affected. Provisional data up to June 2021 show ongoing shortfalls.

Reduced access to TB diagnosis and treatment has resulted in an increase in TB deaths. Best estimates for 2020 are 1.3 million TB deaths among HIV-negative people (up from 1.2 million in 2019) and an additional 214 000 among HIV-positive peoplea (up from 209 000 in 2019), with the combined total back to the level of 2017. Declines in TB incidence (the number of people developing TB each year) achieved in previous years have slowed almost to a halt. These impacts are forecast to be much worse in 2021 and 2022.

Other impacts include reductions between 2019 and 2020 in the number of people provided with treatment for drug-resistant TB (-15%, from 177 100 to 150 359, about 1 in 3 of those in need) and TB preventive treatment (-21%, from 3.6 million to 2.8 million), and a fall in global spending on TB diagnostic, treatment and prevention services (from US$ 5.8 billion to US$ 5.3 billion, less than half of what is needed).

Actions to mitigate and reverse these impacts are urgently required. The immediate priority is to restore access to and provision of essential TB services such that levels of TB case detection and treatment can recover to at least 2019 levels, especially in the most badly-affected countries.
a Officially classified as deaths from HIV/AIDS.

Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic
14 October 2021
The COVID-19 pandemic has reversed years of global progress in tackling tuberculosis and for the first time in over a decade, TB deaths have increased, according to the World Health Organization’s 2021 Global TB report.

In 2020, more people died from TB, with far fewer people being diagnosed and treated or provided with TB preventive treatment compared with 2019, and overall spending on essential TB services falling.

“This report confirms our fears that the disruption of essential health services due to the pandemic could start to unravel years of progress against tuberculosis,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This is alarming news that must serve as a global wake-up call to the urgent need for investments and innovation to close the gaps in diagnosis, treatment and care for the millions of people affected by this ancient but preventable and treatable disease.”…

The increase in the number of TB deaths occurred mainly in the 30 countries with the highest burden of TB[1]. WHO modelling projections suggest the number of people developing TB and dying from the disease could be much higher in 2021 and 2022…

WHO estimates that some 4.1 million people currently suffer from TB but have not been diagnosed with the disease or have not officially reported to national authorities. This figure is up from 2.9 million in 2019…

WHO Announces Proposed Members of its Scientific Advisory Group for the Origins of Novel Pathogens (SAGO)

Milestones :: Perspectives :: Research

 

WHO Announces Proposed Members of its Scientific Advisory Group for the Origins of Novel Pathogens (SAGO)
13 October 2021
Following a public call for experts, the World Health Organization (WHO) today announced proposed members of the WHO Scientific Advisory Group for the Origins of Novel Pathogens (SAGO). The SAGO will advise WHO on the development of a global framework to define and guide studies into the origins of emerging and re-emerging pathogens of epidemic and pandemic potential, including SARS-CoV-2.

“The emergence of new viruses with the potential to spark epidemics and pandemics is a fact of nature, and while SARS-CoV-2 is the latest such virus, it will not be the last,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Understanding where new pathogens come from is essential for preventing future outbreaks with epidemic and pandemic potential, and requires a broad range of expertise. We are very pleased with the calibre of experts selected for SAGO from around the world, and look forward to working with them to make the world safer.”

 

Selected from more than 700 applications, the 26 proposed SAGO members have expertise in a range of areas, including epidemiology, animal health, ecology, clinical medicine, virology, genomics, molecular epidemiology, molecular biology, biology, food safety, biosafety, biosecurity, and public health. The composition of the SAGO reflects geographic and gender diversity.

As per WHO processes, there will now be a two-week public consultation period for WHO to receive feedback on the proposed SAGO members and set in place the modalities for the SAGO’s first meeting, which is planned to take place following this consultation period. The final membership to the SAGO is subject to the above-mentioned public consultation period and relevant WHO practices and procedures.

 

Functions of the SAGO 
In its capacity as an advisory body to WHO, the SAGO will have the following functions:
[1] To advise WHO on the development of a WHO global framework to define and guide studies into the origins of emerging and re-emerging pathogens of epidemic and pandemic potential;
[2] To advise WHO on prioritizing studies and field investigations into the origins of emerging and re-emerging pathogens of epidemic and pandemic potential, in accordance with the WHO global framework described in point (1) above;
1. To provide information and views to assist the WHO Secretariat in the development of a detailed
work plan of the SAGO;
2. In the context of SARS-CoV-2 origins:
– To provide the WHO Secretariat with an independent evaluation of all available scientific and
technical findings from global studies on the origins of SARS-CoV-2;
– To advise the WHO Secretariat regarding developing, monitoring and supporting the next series
of studies into the origins of SARS-CoV-2, including rapid advice on WHO’s operational plans to
implement the next series of global studies into the origins of SARS-CoV-2, as outlined in the
Joint WHO-China Global Study of Origins of SARS-CoV-2: China Part report published on 30
March 2021 and advise on additional studies as needed; and
3. To provide additional advice and support to WHO, as requested by the WHO SAGO Secretariat,
which may include participation in future WHO-international missions to study the origins of SARS-
CoV-2 or for other emerging pathogens.

Public notice of proposed new Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) members
13 October 2021 Call for consultation
After careful consideration of all applications submitted to WHO, the following individuals are proposed for membership of the WHO Scientific Advisory Group for the Origins of Novel Pathogens (SAGO). They are to serve in their personal capacities to represent the broad range of disciplines relevant to emerging and re-emerging pathogens. In evaluating the applications submitted, consideration was given to attaining an adequate distribution of technical expertise, geographical representation and gender balance.
Mr Phillip Alviola is an Associate Professor at the Animal Biology Division at the Institute of Biological Sciences, University of the Philippines. He is originally from the Philippines.
Dr Abdullah Assiri is an Assistant Deputy Minister for Preventive Health at the Ministry of Health in Saudi Arabia.  He is originally from the Kingdom of Saudi Arabia.
Dr Stuart Blacksell is a Professor of Tropical Microbiology at the Nuffield Department of Medicine at the University of Oxford. He is originally from Australia.
Dr Inger Damon is the Director of the Division of High Consequence Pathogens and Pathology at the United States Centers for Disease Control and Prevention. She is originally from the United States of America.
Dr Vladimir Dedkov is the Deputy Director for Research at the Pasteur Institute in Russia. He is originally from Russia.
Dr Christian Drosten is a Professor and head of the Institute of Virology at Charité in Germany.  He is originally from Germany.
Dr Elmoubasher Farag is a senior infectious disease epidemiologist and the Head of the Communicable Diseases Control Programs at the Ministry of Public Health in Qatar. He is originally from Sudan.
Dr Thea Fischer is a Professor of virology at the University of Copenhagen and Head of Clinical Research at Nordsjaellands Hospital in Denmark. She is originally from Denmark.
Dr Raman Gangakhedkar is the Dr C.G. Pandit National Chair at the Indian Council of Medical Research in India. He is originally from India.
Dr Nada Ghosn is the head of the Epidemiology Surveillance Program and Medical officer for the Directorate of Prevention at the Ministry of Health, Lebanon. She is originally from Lebanon.
Dr Maria Guzman is the head of the Center for Research, Diagnostic and Reference at the Institute of Tropical Medicine Pedro Kouri in Cuba. She is originally from Cuba.
Dr Christian Happi is a Professor and director at the African Center of Excellence for Genomics of Infectious Disease (ACEGID), Redeemer’s University, Ede, Nigeria. He is originally from Cameroon.
Dr Marion Koopmans is a Professor and the head of the department of the Viroscience at Erasmus MC. She is originally from the Netherlands.
Dr Sowath Ly is the Deputy Head of Epidemiology and Public Health Unit at the Institut Pasteur du Cambodge. He is originally from Cambodia.
Dr Jean-Claude Manuguerra is a research Research Director of the Environment and Infectious Risks Unit, as well as the head for the Emergency Biological Intervention Unit at the Institut Pasteur in France. He is originally from France.
Dr Khin Myint is the head of the Emerging Virus Research Unit at the Eijkman Institute for Molecular Biology in Jakarta, Indonesia. She is originally from Myanmar.
Dr Carlos M. Morel is the Director at the Center for Technological Development in Health at the Oswaldo Cruz Foundation (Fiocruz) and Ministry of Health in Brazil. He is originally from Brazil.
Dr Hung Nguyen-Viet is the co-program leader of Animal and Human Health Program at the International Livestock Research Institute in Kenya. He is originally from Vietnam.
Dr Chinwe Ochu is the Director of the Prevention Programmes and Knowledge Management at the Nigeria Centre for Disease Control. She is originally from Nigeria.
Dr Masayuki Saijo is the Director of the Medical Planning Department Sapporo City Health and Welfare Bureau in Sapporo, Japan. He is originally from Japan.
Dr Rosemary Sang is an advisor and Chief Research Officer at the Centre for Virus Research, Kenya Medical Research Institute (KEMRI), Kenya. She is originally from Kenya.
Dr Katharina Summermatter is the head of the Biosafety Center and Managing Director of the Biosafety Level 3 Laboratory at the Institute for Infectious Diseases at the University of Berne in Switzerland. She is originally from Switzerland.
Dr Marietjie Venter is a Professor of the Zoonotic Arbovirus and Respiratory Virus Research Programme at the Centre for Viral Zoonoses, Department of Medical Virology at the University of Pretoria in South Africa. She is originally from South Africa.
Dr Supaporn Wacharapluesadee is a researcher at the King Chulalongkorn Memorial Hospital, The Thai Red Cross Society and a committee member of Chula School of Global Health, Faculty of Medicine, Chulalongkorn University. She is originally from Thailand.
Dr John Watson is an Honorary Professor at the Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, as well as a Visiting Professor in the Research Department of Infection and Population Health at the University College of London. He is originally from the United Kingdom.
Dr Yungui Yang is the Deputy Director at the Beijing Institute of Genomics at the Chinese Academy of Sciences in China. He is originally from China.
Pursuant to WHO’s rules and practices, and in order to enhance WHO’s management of conflicts of interest, as well as strengthen public trust and transparency in connection with WHO advisory groups involving the provision of technical advice, the names and brief biographies of the individuals selected for SAGO Membership are now disclosed for public notice and comment. Should you wish to comment on any of the individuals, please send your comment to SAGO@who.int  with subject, “Public comments on SAGO members” by 27 October 2021.

Vaccinating poorer countries is vital to the recovery

Milestones :: Perspectives :: Research

 

Editor’s Note:
We will selectively include opinion and analysis from major media sources as below, recognizing the continuing extraordinary volume of COVID coverage globally.

 

Financial Times
October 12, 2021
Opinion The FT View
Vaccinating poorer countries is vital to the recovery
IMF warns uneven pace of immunisation raises risks of economic scarring
The FT editorial board
[Editor’s text bolding]
It would be hard to find an example of a government intervention that has done more good than vaccination efforts against coronavirus. As well as the obvious health benefits, immunising as many people as possible — starting with the most vulnerable — has allowed economies to unlock, workers to return to offices and emergency support measures to wind down. That has helped to produce an economic bounceback in the rich world that has more than paid off the amount invested in vaccinations.

Yet as the IMF points out in its World Economic Outlook, published on Tuesday to coincide with the Fund and the World Bank’s annual meetings in Washington, vaccination efforts are shockingly uneven. That will hold back the global economic recovery: poorer countries will lag even further behind rich ones that have also been better able to use fiscal and monetary stimulus to support their economies. It is imperative now that rich countries make good on their promises to donate vaccines to the Covax initiative, which aims to ensure equitable global access. They should also lean on drugs companies to do their part in ensuring poorer countries gain access to life-saving jabs.

The IMF warns that the momentum behind the global recovery has faded. It rightly notes current supply chain disruptions underline the need for central banks to be “very, very vigilant” over spiralling inflation expectations getting out of hand. But it identifies the fundamental problem as “the continued grip of the pandemic on global society”. Not only is this holding back the recovery in international services trade such as tourism, and contact-heavy activities such as hospitality; it is also contributing to the supply chain troubles as coronavirus outbreaks have led to factory shutdowns. Global co-operation to immunise the developing world, then, is not only a humanitarian good but in rich countries’ self-interest.

However, only about a fifth of the 850m doses pledged by G7 countries to Covax in June had been delivered by September. It is understandable that governments were reluctant to give away scarce vaccines earlier this year when rich countries themselves were bitterly divided over exporting them to one another. But given the success of rollouts to date, it is now largely vaccine hesitancy rather than supply issues that is holding back take-up among those still unjabbed in rich countries. Now that economies are reopening, export controls should also be eased on medical equipment.

The pace of vaccinations is one of the biggest influences on the IMF’s estimates of “medium term scarring” from the pandemic. While, in aggregate, rich economies are expected to be 0.9 per cent bigger than before the pandemic by 2024, poorer countries, excluding China, are expected still to be 5.5 per cent smaller — undoing much of the poverty reduction over the past decade. The US, thanks to extraordinary stimulus efforts, is expected to have “negative scarring” as Covid-19 accelerated efforts to renew infrastructure, as well as the green transition.

Vaccine manufacturers, too, have a duty to do more to increase access to their products and lower the cost. While Moderna and BioNTech, which produces a vaccine with Pfizer, have both pledged to move production to Africa, details are still scant and it will take time for such production to come online. As the IMF points out, the longer the pandemic continues, the less able countries will be to keep on spending to offset the continued economic harm. Rich countries got a head start in the race to vaccinate; now, in everybody’s interest, they must redouble their efforts to help others catch up.

WTO -TRIPS

Milestones :: Perspectives :: Research

 

WTO -TRIPS

Members pursue convergence for an IP COVID-19 response
World Trade Organization
14 October 2021
At a meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) on 13-14 October 2021, WTO members noted encouraging exchanges at recent small group discussions and bilateral meetings which helped to identify points of convergence on how to provide a common intellectual property (IP) response to COVID-19. The chair of the TRIPS Council, Ambassador Dagfinn Sørli of Norway, announced he would continue to consult with members on how to move towards a consensus before the WTO’s 12th Ministerial Conference (MC12), to be held on 30 November — 3 December

Members appreciated the opportunities provided by recent small group and bilateral meetings to discuss issues related to the scope and implementation of the revised TRIPS waiver proposal first put forward by South Africa and India (IP/C/W/669/Rev.1) as well as the proposal for a draft General Council Declaration on the TRIPS Agreement and Public Health in the circumstances of a pandemic (IP/C/W/681) from the European Union, particularly with regards the use of current TRIPS compulsory licensing provisions.

Some delegations said that the results of those discussions were “encouraging” and helped to identify “important points of convergence”. Others said that further conversations that move the TRIPS Council towards evidence-based and pragmatic solutions should be the next step guiding their discussions at this critical juncture, with only seven weeks left before MC12.

Co-sponsors of the TRIPS waiver proposal reiterated that this initiative should be an integral part of any successful MC12 outcome and urged members to move beyond the binary approach between the two proposals on the table and engage constructively to secure consensus. Members also underlined the importance of aligning the facilitation process under Ambassador David Walker of New Zealand and the work by the TRIPS Council chair, so that a comprehensive package on trade and health leading to a multilateral and horizontal response to the COVID-19 pandemic can be achieved.

Some members noted the consensus-based nature of the WTO and the complexity of the issues involved, and flagged the risk of not achieving an outcome unless delegations are able to make some real compromises. A positive and meaningful outcome at MC12 on the IP response to the pandemic would not only send a powerful message of global solidarity, but would also be proof that the WTO has the ability to respond to a major global crisis, these members added…

Members noted the WTO Secretariat’s updated compilation “COVID-19: Measures Regarding Trade-Related Intellectual Property Rights” that is available on the WTO website. This non-exhaustive list, compiled from official sources, represents an informal situation report and an attempt to provide transparency with respect to measures related to intellectual property rights taken in the COVID-19 context. The chair stressed that the list is updated continuously, even if the rate at which new measures are brought to the Secretariat’s attention is slowing down…

COVID Vaccines – OCHA:: HDX

Milestones :: Perspectives :: Research

 

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
16 Oct 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA
Global COVID-19 Figures: 239M total confirmed cases; 4.9M total confirmed deaths
Global vaccines administered: 6.64B
Number of Countries: 29 [29 week ago]
COVAX Allocations Round 4-6 (Number of Doses): 120M [120M week ago]
COVAX Delivered (Number of Doses): 110M [98M week ago]
Other Delivered (Number of Doses): 190M [160M week ago]
Total Delivered (Number of Doses): 300M [260M week ago]
Total Administered (Number of Doses): 240M [230M week ago]

World Bank Vaccine Operations Portal

Milestones :: Perspectives :: Research

 

World Bank Vaccine Operations Portal
https://www.worldbank.org/en/who-we-are/news/coronavirus-covid19/world-bank-support-for-country-access-to-covid-19-vaccines
As of October 8, 2021, the World Bank approved operations to support vaccine rollout in 61 countries amounting to $5.8 billion. See the latest project financing, project documents and procurement information in the list here. More information will be shared here as it becomes available. 

Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

Milestones :: Perspectives :: Research

 

Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]
A joint initiative from the International Monetary Fund, World Bank Group, World Health Organization, and World Trade Organization to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries. Website accessed 16 Oct 2021: https://data.covid19taskforce.com/data The global view below is complemented by country-specific dashboards here.

Coronavirus [COVID-19] – WHOPublic Health Emergency of International Concern (PHEIC)

Milestones :: Perspectives :: Research

::::::

 

Coronavirus [COVID-19] – WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

 

Weekly Epidemiological and Operational updates
Last update: 16 Oct 2021
Confirmed cases :: 239 437 517 [236 599 025 week ago]
Confirmed deaths :: 4 879 235 [4 831 486 week ago]
Vaccine doses administered: 6 495 672 0 32 [ 6 262 445 422 week ago]

 

:::::::

Weekly epidemiological update on COVID-19 – 13 October 2021
Overview
Globally, the numbers of weekly COVID-19 cases and deaths has continued to decline since late August. Over 2.8 million new cases and over 46 000 new deaths were reported during the week of 4 to 10 October 2021, representing a 7% and 10% decrease respectively, as compared to the previous week. Apart from the European Region, which reported a 7% increase in new weekly cases, all the other regions reported a decline. The largest decrease in new weekly cases was reported from the African Region (32%), followed by the Western Pacific Region (26%). The cumulative number of confirmed cases reported globally is now over 237 million and the cumulative number of deaths is over 4.8 million.
The number of new weekly deaths reported, showed a large (>10%) decline for all regions except for the European Region, which reported an increase of 11% as compared to the previous week. The largest decline in weekly deaths was reported from the Western Pacific and the African Regions, with both showing a 34% decline as compared to the previous week.
In this edition, we provide an update on SARS-CoV-2 Variants of Concern (VOCs) Alpha, Beta, Gamma and Delta along with their geographical distribution.

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 29 September 2021

Milestones :: Perspectives :: Research

 

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 29 September 2021
For 23 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[Full scale view available at title ling above]

 

::::::

COVID Vaccine Developer/Manufacturer Announcements
[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

 

AstraZeneca
Press Releases
AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial
11 October 2021
:: Trial met primary endpoint
:: AZD7442 is the only long-acting antibody combination shown to both prevent and treat COVID-19

BioCubaFarma – Cuba
Últimas Noticias – [Website not responding at inquiry; receiving 403-Forbidden]

 

CanSinoBIO
News – [Website not responding at inquiry]

Clover Biopharmaceuticals – China
News – No new digest announcements identified

 

Curevac [Bayer Ag – Germany]
News
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
October 12, 2021
:: COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK
:: First-generation vaccine candidate, CVnCoV, to be withdrawn from regulatory review due to potential overlap with approval timelines for a second-generation candidate

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements identified

 

Janssen/JNJ
Press Releases
Oct 15, 2021 United States
Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
:: Recommendation informed by Phase 3 findings showing a booster increased protection to 94 percent against moderate to severe/critical COVID-19 in the U.S.
:: Johnson & Johnson COVID-19 vaccine, when given as a booster or primary dose, was generally well-tolerated
:: FDA to decide whether to authorize a booster dose in the coming days

 

Moderna
Press Releases
October 14, 2021
Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.
:: Positive unanimous vote for mRNA-1273 booster at the 50 µg dose level for individuals aged 65 and older as well as individuals aged 18 through 64 at high risk of contracting COVID-19 at least 6 months after completion of the primary series
:: Company estimates that booster at the 50 µg dose level could result in up to 1 billion additional doses

October 12, 2021
Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022

 

Novavax
Press Releases
Complete PREVENT-19 Phase 3 Clinical Trial Results Manuscript for COVID-19 Vaccine Posted to medRxiv Oct 11, 2021 [https://www.medrxiv.org/content/10.1101/2021.10.05.21264567v1 ]

 

Pfizer
Recent Press Releases – No new digest announcements identified

 

Sanofi Pasteur
Press Releases
Update from Sanofi regarding Kevzara® (sarilumab): Supply constraints anticipated until early 2022
October 12, 2021
:: Sanofi is currently experiencing an increase in worldwide demand for sarilumab (Kevzara®) due to an increase in the global demand for IL-6 receptor blockers and the temporary tocilizumab shortage.1
:: Due to this exceptional demand, supply for all four formats of sarilumab (150mg or 200mg pre-filled syringe or auto-injector) is expected to be constrained until early 2022 based on current forecasts.
:: Various country and global health authorities have recommended IL-6 receptor blockers for the treatment of patients with severe or critical COVID-19. Sarilumab is not approved or authorized for emergency use for the treatment of COVID-19 anywhere in the world, and Sanofi will continue to prioritize access for indicated patients with rheumatoid arthritis.
:: Sanofi is working diligently to manage supply to minimize the impact of this increase in demand, and we are committed to proactive and timely communication as the situation evolves.

 

Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified

 

Sinopharm/WIBPBIBP
News – No new digest announcements identified

 

Sinovac
Press Releases – No new digest announcements identified

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

 

::::::

GSK
Press releases for media – No new digest announcements identified

 

Merck
News releases
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older
October 15, 2021

Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
October 15, 2021

 

SK Biosciences
Press releases – No new digest announcements identified

Duke – Launch and Scale Speedometer

Milestones :: Perspectives :: Research

 

Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity
A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution
[accessed 24 July 2021]
See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

 

 

Global Dashboard on COVID-19 Vaccine Equity

Milestones :: Perspectives :: Research

 

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 16 Oct 2021]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

Coronavirus (COVID-19) Vaccinations [Accessed 16 Oct 2021]

Milestones :: Perspectives :: Research

 

Our World in Data
Coronavirus (COVID-19) Vaccinations [Accessed 16 Oct 2021]
:: 47.4% of the world population has received at least one dose of a COVID-19 vaccine.
:: 6.64 billion doses have been administered globally, and 21.41 million are now administered each day.
:: Only 2.7% of people in low-income countries have received at least one dose.

White House [U.S.]

White House [U.S.]
Briefing Room – Selected Major COVID Announcements
Remarks by President Biden on the COVID-⁠19 Response and Vaccination Program
October 14, 2021 • Speeches and Remarks

Statement by National Security Advisor Jake Sullivan on the Global Health Security Agenda Annual Report
October 14, 2021 • Statements and Releases
Today, we are releasing the annual report, “Strengthening Health Security Across the Globe: Progress and Impact of United States Government Investments in the Global Health Security Agenda,” which details our progress and impact helping countries build health security capacity through the Global Health Security Agenda (GHSA) in fiscal year 2020. We are bringing a whole-of-government effort to address global health as a national security imperative, and this report describes how GHSA investments have been critical in advancing the COVID-19 response, and outlines our strategic approach for assisting countries to meet specific targets…
Strengthening Health Security Across the Globe: Progress and Impact of United States Government Investments in the Global Health Security Agenda
Global Health Security Agenda – 2020 Annual Report :: 34 pages

Press Briefing by White House COVID-⁠19 Response Team and Public Health Officials
October 13, 2021 • Press Briefings

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

 

European Medicines Agency
News & Press Releases
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021 (new)
CHMP, Last updated: 15/10/2021

 

 

News: EMA starts rolling review of Evusheld (tixagevimab and cilgavimab) (new)
CHMP, Last updated: 14/10/2021

 

 

News: EMA ends rolling review of CVnCoV COVID-19 vaccine following withdrawal by CureVac AG (new)
Last updated: 12/10/2021

 

 

News: EMA receives application for marketing authorisation for Ronapreve (casirivimab / imdevimab) for treatment and prevention of COVID-19 (new)
CHMP, PDCO, PRAC, Last updated: 11/10/2021

 

 

::::::

 

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
Latest Updates
News
ECDC supports Member States to increase COVID-19 vaccination acceptance and uptake in the EU/EEA
News story – 15 Oct 2021

Publication
Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA
Technical report – 15 Oct 2021

 

 

::::::

Accessed 16 Oct 2021
https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab

 

 

::::::
European Commission
https://ec.europa.eu/commission/presscorner/home/en
Press release 12 October 2021
Afghanistan: Commission announces €1 billion Afghan support package
During the G20 meeting on Afghanistan, President of the European Commission, Ursula von der Leyen, will announce a support package worth around €1 billion for the Afghan people and neighbouring countries, addressing the urgent needs in the country and the region.

Press release 11 October 2021
EU announces vital €92 million contribution in support of UNRWA’s operations
The European Union has disbursed an essential payment of €92 million to the United Nations Relief and Works Agency for Palestine Refugees (UNRWA).

Questions and answers 11 October 2021
Questions and Answers: Proposal to amend EU Budget for 2021 to support global vaccination and funding for global emergencies.
… What is Draft Amending Budget 6 about? 
Draft Amending Budget 6 is about providing additional support to policy areas, which need reinforcement in view of recent developments and additional needs.
More concretely, with the additional funds that Draft Amending Budget 6 will provide, the EU will be able to help speed up global vaccinations, ensure funding for global emergencies like repatriation flights from Afghanistan, reinforce the EU response to the disasters in Haiti and outstanding operations including fighting forest fires and address other pending issues.
Why is the Commission proposing to reinforce the Neighbourhood, Development and International Cooperation Instrument?
With less than 1% of global doses of vaccine for COVID-19 having been administered in low and lower-middle income countries, there is a clear and pressing need to speed up global vaccinations. The EU has already committed to share 250 million doses and stands ready to provide an additional 200 million doses to low and middle income countries through COVAX, at the latest by mid-2022. To secure these extra doses, a total of €1.3 billion will be needed. Of this total amount, €850 million are already available within existing EU budget instruments. The Draft Amending Budget 6 will provide the additional €450 million that are still needed to reach the full €1.3 billion. This is possible by mobilising the EU Flexibility Instrument, which is specifically designed to provide funding for new or unforeseen policy developments…

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

Accesses 16 Oct 2021. Full scale, interactive dashboard available at:
https://africacdc.org/covid-19-vaccination/

Six in seven COVID-19 infections go undetected in Africa
Brazzaville, 14 October 2021 – A new assessment by the World Health Organization (WHO) shows that only 14.2% – or one in seven – COVID-19 infections are being detected in Africa. To reverse that trend and curb transmission, the WHO Regional Office for Africa today announced a new initiative to enhance community screening for COVID-19 in eight countries. The programme aims to reach more than 7 million people with rapid diagnostic tests in the next year…

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment
Russia: Sputnik V – “the first registered COVID-19 vaccine”
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
Fortune – Russia has big plans for the Sputnik vaccine, and big warnings for ‘the Big Pharma lobby’: cut out the attacks
Press release, 15.10.2021

Interim results of a pioneering combination study in Argentina with more than 1,000 participants confirm the one-shot Sputnik Light vaccine (the first component of the Sputnik V vaccine) is an effective universal booster for vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino inducing strong immune response and showing high safety profile. Combination of AstraZeneca and Sputnik Light vaccines showed high immunogenicity results
Press release, 14.10.2021

One-shot Sputnik Light vaccine (first component of the Sputnik V vaccine) demonstrates 70% efficacy against infection with the Delta variant during the first three months after vaccination, Gamaleya Center analysis shows
Press release, 13.10.2021

Sputnik V team statement on fake news in UK media
Press release, 11.10.2021

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

 

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

 

 

Government of India – Press Information Bureau
Latest Press Releases
COVID-19 Vaccination Update – Day 274
:: India’s cumulative vaccination coverage crosses 97.62 crore
:: More than 38 lakh Vaccine doses administered today till 7 pm
Posted On: 16 OCT 2021 9:29PM by PIB Delhi
India’s COVID-19 vaccination coverage has crossed 97.62 Crore(97,62,92,346) today. More than 38 lakh (38,27,173) Vaccine Doses have been administered till 7 pm today.  The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late tonight.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified

POLIOPublic Health Emergency of International Concern (PHEIC)

Emergencies

POLIO
Public Health Emergency of International Concern (PHEIC)
https://polioeradication.org/polio-today/polio-now/this-week/

Polio this week as of 13 October 2021
:: In Ukraine, one case of polio caused by circulating vaccine-derived poliovirus type 2 (cVDPV2), has been confirmed.  A cVDPV2 was isolated from a 17-month old girl with acute flaccid paralysis, from Rivne province (in the north-west of the country), and from six healthy contacts (siblings of the girl). Read more
:: Following careful review of safety and genetic stability data from mass immunization campaigns conducted with the novel oral polio vaccine type 2 (nOPV2), the Strategic Advisory Group of Experts on immunization (SAGE) endorsed the transition to the next use phase for the vaccine. Read more

 

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):
:: Côte d’Ivoire: one cVDPV2 case
:: Nigeria: 18 cVDPV2 cases
– Tajikistan: four cVDPV2 positive environmental samples
– Ukraine: one cVDPV2 case

 

::::::
::::::

WHO/OCHA Emergencies

Health emergencies list – WHO
“The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences.”
Afghanistan crisis [Last apparent update: 22 September 2021]

Crisis in Northern Ethiopia [Last apparent update: 5 Aug 2021]

Ebola outbreak, Democratic Republic of the Congo, 2021 [Last apparent update: 17 Aug 2021]

Ebola outbreak outbreak, N’Zerekore, Guinea, 2021 [Last apparent update: 17 Aug 2021]

Coronavirus disease (COVID-19) pandemic [See COVID above]

 

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020
[Last apparent update: 17 Aug 2021]

Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020
[Last apparent update: 17 Aug 2021]

Ebola outbreak, Democratic Republic of the Congo, 2018 [Last apparent update: 24 July 2018]

Yemen crisis [Last apparent update: 12 February 2021]

Syria crisis [Last apparent update: 18 June 2021]

Somalia crisis [Last apparent update: 24 March 2018]

Nigeria crisis
:: Case study: Pilot implementation in Nigeria and Zambia, SBI COVID-19 data collection tool
1 October 2021

Ebola outbreak, Democratic Republic of the Congo, 2017 [Last apparent update: 17 Aug 2021]

Zika virus disease outbreak, 2015-2016 [Last apparent update: 24 Jan 2020]

Ebola outbreak: West Africa, 2014-2016 [Last apparent update: 17 Aug 2021]

Iraq crisis [Last apparent update: 9 Jan 2008]

South Sudan crisis [Last apparent update: 23 Sep 2020]

Avian influenza A (H7N9) virus outbreak [Last apparent update: 13 September 2021]

Middle East respiratory syndrome (MERS-CoV) outbreak [Last apparent update: 8 July 2019]

Influenza A (H1N1) virus, 2009-2010 pandemic [Last apparent update: 10 Aug 2010]

 

::::::

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
 Afghanistan: Weekly Humanitarian Update (4 – 10 October 2021)

 

Northern Ethiopia
Ethiopia – Northern Ethiopia Humanitarian Update Situation Report, 14 Oct 2021
HIGHLIGHTS
Some 211 trucks of humanitarian supplies arrived in Tigray last week, up from 80 trucks a week before. Although an improvement, this is still insufficient to meet the needs.
More than 145,000 people received food aid in Tigray (30 September-6 October). Some 870,000 people need to be reached per week to serve 5.2 million people in a six-week cycle.
Partners also reached almost 640,000 people with food aid in Amhara Region since early August, and about 72,000 internally displaced people in Afar Region.
Vaccines and logistical support, including fuel, are required to vaccinate more than 887,000 children for polio and more than 790,000 children for measles to avoid outbreaks.
Many humanitarian partners in Tigray significantly reduced and/or halted response programs due to lack of fuel, cash and supplies.

 

::::::
::::::

WHO & Regional Offices [to 16 Oct 2021]

WHO & Regional Offices [to 16 Oct 2021]
https://www.who.int/
15 October 2021
Departmental news
Webinar: Policies to develop, attract, recruit and retain health workers in rural and remote areas, and promote gender equality for rural women through health workforce policies

15 October 2021
Departmental news
Investing $1 per person per year in hand hygiene could save hundreds of thousands of lives

14 October 2021
News release
Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic
[See Milestones above for detail]

13 October 2021
News release
WHO Director-General Bestows Posthumous Award on the Late Henrietta Lacks

13 October 2021
News release
WHO Announces Proposed Members of its Scientific Advisory Group for the Origins of Novel Pathogens (SAGO)
[See Milestones above for detail]

11 October 2021
News release
WHO’s 10 calls for climate action to assure sustained recovery from COVID-19

11 October 2021
Departmental news
International Day of the Girl Child

11 October 2021
Departmental news
New stress management course for people living with adversity

10 October 2021
Departmental news
SAGE October 2021 meeting highlights
[See Milestones above for detail]

::::::

 

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Six in seven COVID-19 infections go undetected in Africa
Brazzaville, 14 October 2021 – A new assessment by the World Health Organization (WHO) shows that only 14.2% – or one in seven – COVID-19 infections are being detected in Africa. To reverse that trend and curb transmission, the WHO Regional Office for Africa today announced a new initiative to enhance community screening for COVID-19 in eight countries. The programme aims to reach more than 7 million people with rapid diagnostic tests in the next year…
:: Democratic Republic of the Congo starts Ebola vaccination 13 October 2021
:: Uganda’s community initiative helping HIV patients overcome depression 10 October 2021
:: Access to mental health and psychosocial support services remains unequal for children and adolescents in Africa, alert UNICEF & WHO 10 October 2021

WHO Region of the Americas PAHO
No new digest content identified

WHO South-East Asia Region SEARO
:: Health and Education Ministers, heads of partner agencies commit to health promoting schools for all in WHO South-East Asia Region 12 October 2021

WHO European Region EURO
:: One case of polio detected in Ukraine 13-10-2021
:: WHO/Europe launches Western Balkans Digital Health Network 13-10-2021
:: Moldovan pharmacies contribute to pandemic response as a reliable source of information on COVID-19 vaccination 12-10-2021
:: WHO Regional Director for Europe visits Turkmenistan 12-10-2021
:: Protecting the mental health of health workers: hope and resilience in Kazakhstan 11-10-2021

WHO Eastern Mediterranean Region EMRO
No new digest content identified

WHO Western Pacific Region
No new digest content identified

 

::::::

New WHO Publications [Selected]
https://www.who.int/publications/i
Selected Titles
15 October 2021
State of the world’s hand hygiene

15 October 2021
WHO Drug Information – Volume 35, No. 3

14 October 2021
Global tuberculosis report 2021

13 October 2021
Fair Play: Building a strong physical activity system for more active people

13 October 2021
WHO Costing and Budgeting Tool for National Action Plans on Antimicrobial Resistance

11 October 2021
COP26 Special Report on Climate Change and Health

CDC/ACIP [U.S.] [to 16 Oct 2021]

CDC/ACIP [U.S.] [to 16 Oct 2021]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases, Announcements

Next ACIP Meetings
No registration is required to watch the webcast.
:: October 20-21, 2021 – Draft Agenda – October 20-21, 202
:: November 2-3, 2021 – No agenda posted at 16 Oct 2021

MMWR News Synopsis Friday, October 15, 2021
Selected Content
Vaccination Coverage by Age 24 Months Among Children Born in 2017 and 2018 — National Immunization Survey-Child, United States, 2018–2020
New CDC data show that prior to the COVID-19 pandemic, most parents in the U.S. continued to protect their children by following CDC’s Advisory Committee on Immunization Practices (ACIP) recommended vaccine schedule. However, there are disparities in vaccination coverage based on health insurance status, race/ethnicity, poverty level, and jurisdiction. Despite challenges caused by the COVID-19 pandemic, it is important to remain vigilant to ensure that children get the vaccines they need and catch up on any missed doses to protect them against serious and sometimes deadly diseases.
While routine vaccination among children remains high, parents and providers should use any clinician visit as an opportunity for the child to get recommended vaccinations that are due or might have been missed because of COVID-related disruptions. According to the latest National Immunization Survey-Child (NIS-Child), during 2018-2020, over 90% of children were fully vaccinated against measles, mumps, and rubella (MMR), polio, hepatitis B, and varicella by age 24 months. While CDC’s Vaccines for Children (VFC) Program helps provide vaccines to children whose families may not be able to afford them, the study found that barriers to health care access associated with health insurance status and poverty level may keep some parents from getting their children vaccinated.

Coronavirus Disease 2019 (COVID-19)– CDC
Approximately 25 announcements/reports/data summaries.

The Government of Democratic Republic of Congo Reported an Outbreak of Ebola Virus Disease in Beni Health Zone, North Kivu province

Africa CDC [to 16 Oct 2021]
http://www.africacdc.org/
News
The Government of Democratic Republic of Congo Reported an Outbreak of Ebola Virus Disease in Beni Health Zone, North Kivu province
ADDIS ABABA, ETHIOPIA, 9 October 2021: On 8 October 2021, the Democratic Republic of Congo (DRC) Ministry of Public Health, Hygiene, and Prevention (MoH) reported a confirmed death of Ebola virus disease (EVD) in the Beni health zone, North Kivu province. This comes barely five months after the end of the most recent outbreak that was detected in the same province.
The index case is a 3-year-old male, child who died on 6 October in a local health facility after presenting with haemorrhagic symptoms. Samples collected, tested positive for Ebola virus at the Goma reference laboratory.
“We see this with great concern as we are going to fight against multiple disease outbreaks in DRC, including, cholera, monkeypox, yellow fever, meningitis and EVD, on top of the ongoing COVID-19 pandemic” said Dr John Nkengasong, the Director of Africa CDC…

China CDC http://www.chinacdc.cn/en/

China CDC http://www.chinacdc.cn/en/

National Health Commission of the People’s Republic of China [to 16 Oct 2021]
http://en.nhc.gov.cn/
News
Oct 16: Daily briefing on novel coronavirus cases in China
On Oct 15, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 14 new cases of confirmed infections.

Chinese vice-premier stresses COVID-19 containment in fall-winter season
2021-10-12

National Medical Products Administration – PRC [to 16 Oct 2021]
http://english.nmpa.gov.cn/news.html
News
Over 2.225b COVID-19 vaccine doses administered on Chinese mainland
2021-10-15
More than 2.225 billion doses of COVID-19 vaccine had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed on Oct 14.

CCDC Weekly – Weekly Reports: Current Volume (3)
2021-10-15 / No. 42
View  PDF of this issue
:: Preplanned Studies: Assessing Impacting Factors of Dog Owners’ Adoption of Dog Vaccination Against Rabies: A Cross-sectional Survey in Rural Areas — Guangxi Zhuang Autonomous Region, China, 2021
:: Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, August, 2021

Organization Announcements

::::::

 

Organization Announcements
Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 16 Oct 2021]
https://alleninstitute.org/what-we-do/frontiers-group/new s-press/
News
No new digest content identified.

BARDA – U.S. Department of HHS [to 16 Oct 2021]
https://www.phe.gov/about/barda/Pages/default.aspx
News
No new digest content identified.

BMGF – Gates Foundation [to 16 Oct 2021]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 16 Oct 2021]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 16 Oct 2021]
https://carb-x.org/
News
10.12.2021  |
CARB-X 2020-21 Annual Report: CARB-X surpasses all goals in first five years in combatting antibiotic resistant-bacteria
CARB-X closed its fifth fiscal year on July 31, 2021 with US$361 million awarded to 92 projects funding since inception. In its latest fiscal year, CARB-X invested in 25 new projects across all three pillars – preventatives, diagnostics, and therapeutics. This year saw two more successful graduations from the portfolio, four more First-in Human programs launch, and several strategic augmentations of the portfolio including in the areas of: gonorrhea, bacteriophage, vaccines, peptides and polymyxins, and anti-virulence factors.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 16 Oct 2021]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions and posting of all segments of Vaccines and Global Health: The Week in Review are available here.
:: [NEW] Informed Consent: A Monthly Review – October 2021 is now posted here

CEPI – Coalition for Epidemic Preparedness Innovations [to 16 Oct 2021]
http://cepi.net/
Latest News
Could chicken eggs help end the COVID-19 pandemic?
CEPI is supporting PATH’s work as part of an international consortium developing a new egg-based vaccine to tackle COVID-19, inspired by influenza vaccines in longtime use.
11 Oct 2021

 

CEPI opens Call to evaluate fractional COVID-19 booster and third shots as part of efforts to stretch global vaccine supply
CEPI will make up to US $25m funding available as part of the Call, with the intention to fund several clinical trials looking at dose-sparing booster shots for different COVID-19 vaccine candidates.
11 Oct 2021

DARPA – Defense Advanced Research Projects Agency [to 16 Oct 2021
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center [to 16 Oct 2021]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP [to 16 Oct 2021]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
12 October 2021
First EDCTP and Africa CDC-supported Epidemiologists and Biostatisticians start their training

Emory Vaccine Center [to 16 Oct 2021]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 16 Oct 2021]
http://www.euvaccine.eu/
Latest News
No new digest content identified.

Fondation Merieux [to 16 Oct 2021]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

Gavi [to 16 Oct 2021]
https://www.gavi.org/
News releases
11 October 2021
Vigne des Nations: 2020 vintage awarded to Gavi by Geneva Canton, for its action for global health
… This recognition honours the commitment of this organisation to guaranteeing fair and equitable access to vaccines around the world…

11 October 2021
First Swiss-donated doses ship to Sierra Leone, as part of 4 million dose pledge

GHIT Fund [to 16 Oct 2021]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 212 with the aim of developing new tools to tackle infectious diseases that
No new digest content identified.

Global Fund [to 16 Oct 2021]
https://www.theglobalfund.org/en/news/
News & Stories
News
Drug-resistant TB: Business as usual no longer an option
14 October 2021 by Dr. Mohammed Yassin, Global Fund Senior Tuberculosis Advisor

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 16 Oct 2021]
https://www.glopid-r.org/news/
News
No new digest content identified.

Hilleman Laboratories [to 16 Oct 2021]
http://www.hillemanlabs.org/
Website reports “under maintenance” at inquiry

Human Vaccines Project [to 16 Oct 2021]
http://www.humanvaccinesproject.org/
News
HVP COVID Report
Oct 15, 2021
Kristen Jill Abboud: Should We Get Back to Worrying About the Flu?

IAVI [to 16 Oct 2021]
https://www.iavi.org/newsroom
Latest News
No new digest content identified.

 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

ICRC [to 16 Oct 2021]
https://www.icrc.org/en/whats-new
Selected News Releases, Statements, Reports
Ahead of COP26, Red Cross Red Crescent Movement’s five asks to world leaders: “It is not too late to act: the survival of humanity depends on the actions we take today”
14/10/2021

 

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC [to 16 Oct 2021]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
14/10/2021
Ahead of COP26, Red Cross Red Crescent Movement’s five asks to world leaders: “It is not too late to act: the survival of humanity depends on the actions we take today”

14/10/2021
Palau and Cook Islands lead the world on COVID-19 vaccinations
Kuala Lumpur/Suva, 14 October 2021 – The small Pacific country of Palau has more than 99 per cent of its eligible population fully vaccinated, contesting top spot in the world for COVID-19 vaccination rates, according to government data.
Other Pacific nations have also raced up the global vaccine leader board. The Cook Islands has 96 per cent of the eligible population fully vaccinated while 96 per cent have received their first jab in Fiji, according to Cook Islands and Fiji Government data...

Institut Pasteur [to 16 Oct 2021]
https://www.pasteur.fr/en/press-area
Press Documents
No new digest content identified.

IOM / International Organization for Migration [to 16 Oct 2021]
http://www.iom.int/press-room/press-releases
News – Selected
News 15 Oct 2021
Free Movement of People a Top Priority, Say West African Nations

News 12 Oct 2021
Global Migration Under Spotlight at EU-IOM Strategic Cooperation Meeting

ISC / International Science Council [to 16 Oct 2021]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
News Press
Sir Peter Gluckman, paediatrician, biomedical scientist and science-policy expert becomes President of the International Science Council
14.10.2021

News Press
New Governing Board elected to provide scientific and strategic leadership to the International Science Council
14.10.2021
… “The new Board takes on leadership of the ISC at a critical time and I am honoured and privileged to be given the responsibility of chairing the Board,” said Peter Gluckman, incoming President of the ISC. Membership of the Governing Board reflects the multi-disciplinarity of the Council’s membership base, as well as regional and gender diversity.
The new Governing Board faces the ongoing challenge of ensuring that science has an increasing impact on the multilateral agenda. The natural and social sciences have a critical role to play as the world faces complex challenges from COVID-19 to climate change, and from conflict reduction to inequality, health inequalities, poverty, food, water and energy challenges, and coexistence with rapidly advancing technologies. These issues are compounded by disinformation and the politicisation of knowledge. At the same time, the nature and conduct of science is changing rapidly and the ISC has a critical role to play in working with the scientific community, the policy community and society to ensure better outcomes for people and the planet.
Amongst its duties, the Governing Board provides strategic leadership and develops priority activity and business plans for approval by the General Assembly, as well as monitoring the implementation and performance of such plans. The Board oversees the scientific activities and other operations of the Council and reports to the General Assembly, as well as proposing budgetary outlines and the scale of annual dues to be paid by Members…

News Press
Ten outstanding individual scientists and organizations celebrated in first ever ISC Awards
13.10.2021

IVAC [to 16 Oct 2021]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

IVI [to 16 Oct 2021]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security [to 16 Oct 2021]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
No new digest content identified.

MSF/Médecins Sans Frontières [to 16 Oct 2021]
http://www.msf.org/
Latest [Selected Announcements]
Haiti
Two months after the earthquake, health needs remain high
Project Update 15 Oct 2021

Lebanon
Breaking barriers to mental health care in Lebanon
Project Update 14 Oct 2021

Syria
Worst wave yet of COVID-19 in northern Syria overwhelms health system
Press Release 13 Oct 2021

Mental health
Mental health care needs enormous around the world
Project Update 10 Oct 2021

National Academy of Medicine – USA [to 16 Oct 2021]
https://nam.edu/programs/
Selected News/Programs/Events
Oct 2021
Crossing the Policy and Equity Chasm: Lessons from Compounding Health Crises (NAM Annual Meeting 2021)
Time: 8:00 AM
The National Academy of Medicine will hold its annual meeting on Sunday and Monday, October 17-18, 2021. Due to the ongoing COVID-19 pandemic and in an abundance of caution, the Annual Meeting will be held entirely virtually. In order to help support this event, the symposium will cost $50 to attend live on October 17 and 18.

National Academy of Sciences – USA [to 16 Oct 2021]
http://www.nasonline.org/news-and-multimedia/
News
No new digest content identified.

National Vaccine Program Office – U.S. HHS [to 16 Oct 2021]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

NIH [to 16 Oct 2021]
http://www.nih.gov/news-events/news-releases
News Releases
Antibody treatment for MIS-C works by depleting inflammatory immune cells
October 15, 2021 — NIH-funded study explains how intravenous immune globulin helps children with rare COVID condition.

NIH RADx initiative expands COVID-19 testing innovation for additional types of rapid tests
October 14, 2021 — The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.

New, highly innovative NIH research awards to address health disparities and advance health equity
October 13, 2021 — Eleven grants were awarded to support the work of exceptionally creative researchers across the United States through the NIH Common Fund’s Transformative Research to Address Health Disparities and Advance Health Equity initiative.

PATH [to 16 Oct 2021]
https://www.path.org/media-center/
Press Releases
Real-world performance of nOPV2 reinforces strong safety profile
October 11, 2021 by PATH
Experts endorse successful completion of initial use period
The Strategic Advisory Group of Experts on Immunization (SAGE) – an independent group of scientific experts that advises the World Health Organization (WHO) on vaccines and immunization – has endorsed the strong safety performance of nOPV2 use in real-world settings. SAGE reviewed data from the initial use period for nOPV2, which began in November 2020.
Since 2015, PATH has helped advance the development of nOPV2 by serving as the convener of the product development consortium; providing technical input into manufacturing and clinical trials; overseeing the development and execution of novel tests to assess the vaccine’s genetic stability; and facilitating data-sharing among partners.
In November 2020, the vaccine received a recommendation for initial use under WHO’s Emergency Use Listing (EUL) procedure, based on the urgent need to contain outbreaks and on promising clinical data from Phase 1 and Phase 2 nOPV2 trials….
Fact sheet

Sabin Vaccine Institute [to 16 Oct 2021]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

UNAIDS [to 16 Oct 2021]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
13 October 2021
Community mobilization and digital technologies accelerate the response to HIV and COVID-19 in Gabon

12 October 2021
Partnering to strengthen community engagement in the HIV and COVID-19 responses in Namibia

11 October 2021
Helping Haiti build a sustainable HIV response

11 October 2021
People living with HIV at higher risk of COVID-19 illness but have lower access to COVID-19 vaccines

UNHCR Office of the United Nations High Commissioner for Refugees [to 16 Oct 2021]
http://www.unhcr.org/en-us/media-centre.htmlS
Selected News Releases, Announcements
World Food Day: Celebrating efforts to strengthen local food systems for displaced and host communities
13 Oct 2021

UNICEF [to 16 Oct 2021]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
Press release
10/15/2021
UNICEF: 75 years of engagement in and with Europe, but no time to celebrate!
“Bold and effective commitment to children’s rights are important more than ever before in the EU, and with the EU for the world”, says UNICEF’s Deputy Executive Director, Charlotte Petri Gornitza

Press release
10/15/2021
FACT SHEET: On Global Handwashing Day, UNICEF warns that 3 in 10 people do not have basic handwashing facilities at home to fight off infectious diseases

Unitaid [to 16 Oct 2021]
https://unitaid.org/
Featured News
No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 16 Oct 2021]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin) [to 16 Oct 2021]
https://www.vaccineacceptance.org/
Announcements
No new digest content identified.

Vaccine Confidence Project [to 16 Oct 2021]
http://www.vaccineconfidence.org/
News, Research and Reports
Coronavirus global impact
Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

Vaccine Education Center – Children’s Hospital of Philadelphia [to 16 Oct 2021]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

Wellcome Trust [to 16 Oct 2021]
https://wellcome.ac.uk/news
News and reports
No new digest content identified.

The Wistar Institute [to 16 Oct 2021]
https://www.wistar.org/news/press-releases
Press Releases
Press Release
Oct. 14, 2021
Dr. Anthony Fauci and Philadelphia FIGHT’s Jane Shull Receive Wistar Legacy Award at 25th Anniversary of Jonathan Lax Memorial Lecture
Virtual event celebrates local HIV research and advocacy influencers/communities that paved way for global HIV impact

WFPHA: World Federation of Public Health Associations [to 16 Oct 2021]
https://www.wfpha.org/
Latest News
Reducing Maternal Mortality Ratio in low- and Middle Income Countries
Oct 14, 2021
Reducing Maternal Mortality Ratio in low- and Middle-income CountriesThe World Health Organization (WHO) has long identified maternal mortality as a global priority for improving global health outcomes. Yet, the United Nations Millennium…

Policy Statement on Climate Change
Oct 14, 2021
Policy Statement on Climate ChangeClimate change is a global problem. It is harming human health and wellbeing today, and we have clear evidence that lack of effective response will render the global poor, people living in low lying areas, along…

Polio Eradication: Last Battle?
Oct 12, 2021
Polio Eradication: Last Battle?Poliomyelitis (polio) is a highly infectious viral disease that attacks the nervous system and can cause irreversible paralysis and death. There is no cure for polio, it can only be prevented through immunisation….

World Bank [to 16 Oct 2021]
http://www.worldbank.org/en/news/all
Selected News, Announcements
Accelerating COVID-19 Vaccine Uptake to Boost Malawi’s Economic Recovery
Since the onset of the COVID-19 pandemic, many countries including Malawi have struggled to mitigate its impact amid limited fiscal support and fragile health systems. The pandemic has plunged the continent…
Date: October 13, 2021 Type: Opinion

Improving Maternal and Children Health Care in Times of Cholera
Challenge Ten months after a devastating earthquake hit in 2010, a severe cholera outbreak placed additional pressure on Haiti’s already fragile health system, further compromising the welfare and health…
Date: October 13, 2021 Type: Result Brief

Low-Income Country Debt Rises to Record $860 Billion in 2020
Debt reduction, restructuring, and transparency needed to help low-income countries overcome debt challenges
WASHINGTON, Oct. 11, 2021— Governments around the world responded to the COVID-19 pandemic with massive fiscal, monetary, and financial stimulus packages. While these measures were aimed at addressing the health emergency, cushioning the impact of the pandemic on the poor and vulnerable and putting countries on a path to recovery, the resulting debt burden of the world’s low-income countries rose 12% to a record $860 billion in 2020, according to a new World Bank report.
Even prior to the pandemic, many low- and middle-income countries were in a vulnerable position, with slowing economic growth and public and external debt at elevated levels. External debt stocks of low- and middle-income countries combined rose 5.3% in 2020 to $8.7 trillion. According to the new International Debt Statistics 2022 report, an encompassing approach to managing debt is needed to help low- and middle-income countries assess and curtail risks and achieve sustainable debt levels.
“We need a comprehensive approach to the debt problem, including debt reduction, swifter restructuring and improved transparency,” said World Bank Group President David Malpass. “Sustainable debt levels are vital for economic recovery and poverty reduction.”
The deterioration in debt indicators was widespread and impacted countries in all regions. Across all low- and middle-income countries, the rise in external indebtedness outpaced Gross National Income (GNI) and export growth. Low- and middle-income countries’ external debt-to-GNI ratio (excluding China) rose to 42% in 2020 from 37% in 2019 while their debt-to-export ratio increased to 154% in 2020 from 126% in 2019…

World Customs Organization – WCO [to 16 Oct 2021]
http://www.wcoomd.org/
Latest News – Selected Items
13 October 2021
WCO concludes the cycle of regional consultations on the Strategic Plan with the Asia/Pacific region

World Organisation for Animal Health (OIE) [to 16 Oct 2021]
https://www.oie.int/en/media/news/
Press Releases, Statements
No new digest content identified.

WTO – World Trade Organisation [to 16 Oct 2021]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events
Members pursue convergence for an IP COVID-19 response
14 October 2021
At a meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) on 13-14 October 2021, WTO members noted encouraging exchanges at recent small group discussions and bilateral meetings which helped to identify points of convergence on how to provide a common intellectual property (IP) response to COVID-19. The chair of the TRIPS Council, Ambassador Dagfinn Sørli of Norway, announced he would continue to consult with members on how to move towards a consensus before the WTO’s 12th Ministerial Conference (MC12), to be held on 30 November — 3 December
News item
[See COVID above for detail]

WTO briefs members and observers on COVID-19 related initiatives and analysis
12 October 2021
Over 180 representatives from 111 members and observers participated on 12 October in a virtual information session on the WTO Secretariat’s work to support equitable access to COVID-19 vaccines.
Deputy Director-General Anabel González hosted the Virtual Information Session on Access to COVID-19 Vaccines, Collaborative Initiatives and Analysis on Supply Chains and Tariffs. She briefed participants on the Secretariat’s contributions to a range of collaborative initiatives, such as the Multilateral Leaders Task Force on COVID-19, the WHO, WIPO, WTO Trilateral Cooperation in support of capacity building, the COVAX Manufacturing Task Force and the Access to COVID-19 Tools (ACT) Accelerator.
The programme included presentations on the most recent information notes prepared by the WTO Secretariat:
:: update of the Indicative List of Trade-Related Bottlenecks and Trade-Facilitating Measures on Critical Products to Combat COVID-19, a Joint Indicative List of Critical COVID-19 Vaccine Inputs,
:: new report on COVID-19 vaccines production and tariffs on vaccine inputs,
:: comments by the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO).
The recording of the session is available here. The programme and background materials are available here. The WTO COVID-19 gateway is available here.
News item

 

::::::

ARM [Alliance for Regenerative Medicine] [to 16 Oct 2021]
https://alliancerm.org/press-releases/
Selected Press Releases
No new digest content identified.

BIO [to 16 Oct 2021]
https://www.bio.org/press-releases
Press Releases, Letters, Testimony, Comments [Selected]
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 16 Oct 2021]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 16 Oct 2021]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA [to 16 Oct 2021]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
R&D-based pharmaceutical industry’s innovative partnerships to meet urgent global supply needs
05 October 2021

 

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

International Alliance of Patients’ Organizations – IAPO [to 16 Oct 2021]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

PhRMA [to 16 Oct 2021]
http://www.phrma.org/
Latest News [Selected]
New report shows more than 260 medicines in development to fight neurodegenerative diseases
October 12, 2021
Today, PhRMA released a new report detailing the more than 260 medicines in development for 29 neurodegenerative diseases.
Blog Post

Palliative Surgery

AMA Journal of Ethics
Volume 23, Number 10: E757-831
https://journalofethics.ama-assn.org/issue/palliative-surgery

 

Palliative Surgery
Palliative care is not just for dying patients. In fact, dying patients are living patients, and all patients deserve palliation. Contrary to popular belief among many patients and clinicians, palliative interventions can be invasive and include not only medical, but surgical care. In any case, palliative care should be defined by intention: partnering clinicians, patients, and their loved ones aim neither to cure disease nor to prolong life, but to improve the quality of a patient’s life at any needed time. Quality of life is motivated by goal-elucidating conversation, counseling, and symptom management-directed intervention. This issue investigates surgical palliation specifically, with sharp focus on intention formation and trust preservation.

Intention to COVID-19 vaccination and associated factors among health care workers: A systematic review and meta-analysis of cross-sectional studies

American Journal of Infection Control
October 2021 Volume 49 Issue 10 p1215-1342
http://www.ajicjournal.org/current

 

State of the Science Review
Intention to COVID-19 vaccination and associated factors among health care workers: A systematic review and meta-analysis of cross-sectional studies
Chuxuan Luo, et al.
Published online: July 14, 2021
p1295-1304

Implementation of a COVID-19 Mass Vaccination Clinic to College Students in Montana

American Journal of Public Health
October 2021 111(10)
http://ajph.aphapublications.org/toc/ajph/current

 

NOTES FROM THE FIELD
Implementation of a COVID-19 Mass Vaccination Clinic to College Students in Montana
Immunization/Vaccines, Other Race/Ethnicity, Race/Ethnicity
Sally Moyce, Julie Ruff, Ann Galloway and Sarah Shannon
111(10), pp. 1776–1779

COVID-19 Case Rates After Surveillance and Vaccinations in a Statewide Psychiatric Hospital System

American Journal of Public Health
October 2021 111(10)
http://ajph.aphapublications.org/toc/ajph/current

 

NOTES FROM THE FIELD
COVID-19 Case Rates After Surveillance and Vaccinations in a Statewide Psychiatric Hospital System
Immunization/Vaccines, Surveillance, Mental Health, Statistics/Evaluation/Research, Health Care Facilities/Services
Thomas E. Smith, Ian T. Rodgers, Daniel J. Silverman, Sally R. Dreslin, Mark Olfson, Lisa B. Dixon and Melanie M. Wall
111(10), pp. 1780–1783

Levels of explainable artificial intelligence for human-aligned conversational explanations

Artificial Intelligence – An International Journal
Volume 299 October 2021
https://www.sciencedirect.com/journal/artificial-intelligence/vol/299/suppl/C

 

Research article Abstract only
Levels of explainable artificial intelligence for human-aligned conversational explanations
Richard Dazeley, Peter Vamplew, Cameron Foale, Charlotte Young, … Francisco Cruz
Article 103525
This paper aims to define levels of explanation and describe how they can be integrated to create a human-aligned conversational explanation system.

Assessment of the appropriateness of the i-CONSENT guidelines recommendations for improving understanding of the informed consent process in clinical studies

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 16 Oct 2021)

 

Assessment of the appropriateness of the i-CONSENT guidelines recommendations for improving understanding of the informed consent process in clinical studies
The H2020 i-CONSENT project has developed a set of guidelines that offer ethical recommendations and practical tools aimed at making the informed consent process in clinical studies more comprehensive, tailored, and inclusive. An analysis of the appropriateness of some of its novel recommendations was carried out by a group of experts representing different stakeholders.
Authors: Jaime Fons-Martinez, Cristina Ferrer-Albero and Javier Diez-Domingo
Content type: Research
13 October 2021

Knowledge, attitudes and perceptions towards COVID-19 vaccinations: a cross-sectional community survey in Bangladesh

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 16 Oct 2021)

 

Knowledge, attitudes and perceptions towards COVID-19 vaccinations: a cross-sectional community survey in Bangladesh
Several vaccines have been approved for use against coronavirus disease (COVID-19) and distributed globally in different regions. However, general community knowledge, attitudes and perceptions towards COVID-1…
Authors: Md. Saiful Islam, Abu Bakkar Siddique, Rejina Akter, Rafia Tasnim, Md. Safaet Hossain Sujan, Paul R. Ward and Md. Tajuddin Sikder
Citation: BMC Public Health 2021 21:1851
Content type: Research
Published on: 13 October 2021

Determinants of HPV-vaccination uptake and subgroups with a lower uptake in the Netherlands

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 16 Oct 2021)

 

Determinants of HPV-vaccination uptake and subgroups with a lower uptake in the Netherlands
In the Netherlands, the HPV-vaccine uptake was 52% during the 2009 catch-up campaign (birth cohorts 1993–1996). This increased to 61% in the regular immunization program (birth cohorts 2000–2001). However for …
Authors: A. C. de Munter, T. M. Schurink-van t Klooster, A. van Lier, R. Akkermans, H. E. de Melker and W. L. M. Ruijs
Citation: BMC Public Health 2021 21:1848
Content type: Research
Published on: 12 October 2021

The knowledge, attitudes and beliefs of midwives on the vaccination coverage rates in Perth’s Aboriginal children

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 16 Oct 2021)

 

The knowledge, attitudes and beliefs of midwives on the vaccination coverage rates in Perth’s Aboriginal children
Midwives are well placed to promote vaccination awareness throughout a women’s pregnancy and strengthen childhood vaccination demand following hospital discharge. In Perth, Western Australia, Aboriginal childr…
Authors: Rebecca Carman, Lesley Andrew and Amanda Devine
Citation: BMC Public Health 2021 21:1845
Content type: Research
Published on: 12 October 2021

Original research: A mixed methods study to develop a tool to assess institutional readiness to conduct knowledge translation activities in low-income and middle-income countries

BMJ Open
October 2021 – Volume 11 – 10
https://bmjopen.bmj.com/content/11/10

 

Articles
Original research: A mixed methods study to develop a tool to assess institutional readiness to conduct knowledge translation activities in low-income and middle-income countries (11 October, 2021)
Anna Kalbarczyk, Aditi Rao, Olakunle Alonge
This study identifies a tool for assessing readiness of LMIC academic institutions to conduct KT and unique opportunities for building capacity. The organisational focus of these factors underscores the need for strategies that address organisational systems and structures in addition to individual skills. Future research will be conducted to understand determinants of these factors and develop a comprehensive set of capacity building strategies responsive to academic institutions in LMICs.

The surprise element: A hallmark of creativity in scientists, artists, and comedians

Cell
Oct 14, 2021 Volume 184 Issue 21 p5261-5496
https://www.cell.com/cell/current

 

Commentary
The surprise element: A hallmark of creativity in scientists, artists, and comedians
Joseph L. Goldstein
Truly creative works of science and art produce unexpected and surprising results—just like the punch line of a good joke that generates an unfamiliar twist on a familiar idea. Surprise stimulates curiosity, which triggers a search to reveal the mystery of things unknown.

Delivering the message: How a novel technology enabled the rapid development of effective vaccines

Cell
Oct 14, 2021 Volume 184 Issue 21 p5261-5496
https://www.cell.com/cell/current

 

Benchmarks
Delivering the message: How a novel technology enabled the rapid development of effective vaccines
Lucy Shapiro, Richard Losick
This year’s Lasker∼Debakey Clinical Research Award honors Katalin Karikó and Drew Weissman for the development of a therapeutic technology based on nucleoside-modification of messenger RNA, enabling the rapid development of the highly effective COVID-19 vaccines.

Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations

Clinical Pharmacology & Therapeutics
Volume 110, Issue 4 Pages: 827-1135 October 2021
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

 

Review
Open Access
Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations
Emma Hughes, Erika Wallender, Ali Mohamed Ali, Prasanna Jagannathan, Radojka M. Savic
Pages: 926-940
First Published:24 March 2021

Assuring Access to Safe Medicines in Pregnancy and Breastfeeding

Clinical Pharmacology & Therapeutics
Volume 110, Issue 4 Pages: 827-1135 October 2021
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

 

Mini-Review
Open Access
Assuring Access to Safe Medicines in Pregnancy and Breastfeeding
Janet Nooney, Shannon Thor, Corinne de Vries, John Clements, Leyla Sahin, Wei Hua, Darcie Everett, Cosimo Zaccaria, Robert Ball, Agnes Saint-Raymond, Lynne Yao, June Raine, Sandra Kweder
Pages: 941-945
First Published:21 February 2021
Free Access

Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo Framework

Clinical Pharmacology Worldwide: A Global Health Perspective
Larissa Wenning, Goonaseelan (Colin) Pillai, Todd C. Knepper, Katarina Ilic, Ali Mohamed Ali, Jennifer E. Hibma

 

Tutorial
Open Access
Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo Framework
Tjitske M. van der Zanden, Miriam G. Mooij, Nienke J. Vet, Antje Neubert, Wolfgang Rascher, Florian B. Lagler, Christoph Male, Helene Grytli, Thomas Halvorsen, Matthijs de Hoog, Saskia N. de Wildt
Pages: 952-965
First Published:18 June 2021

Policy and planning for large epidemics and pandemics – challenges and lessons learned from COVID-19

Current Opinion in Infectious Diseases
October 2021 – Volume 34 – Issue 5
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx

 

Policy and planning for large epidemics and pandemics – challenges and lessons learned from COVID-19
Sharp, Ashley; Jain, Vageesh; Alimi, Yewande; More
Current Opinion in Infectious Diseases. 34(5):393-400, October 2021.